TrialThe oncologist2015

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

Balazs Halmos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.